葛祥丽,李慧敬,崔明湖,东莹莹.艾司西酞普兰联合奥氮平治疗抑郁症的效果及安全性的Meta分析[J].四川精神卫生杂志,2019,32(6):523-530.
艾司西酞普兰联合奥氮平治疗抑郁症的效果及安全性的Meta分析
Efficacy and safety of escitalopram combined with olanzapinein the treatment of depression: a Meta-analysis
投稿时间:2019-09-03  
DOI:10.11886/scjsws20190903001
中文关键词:  艾司西酞普兰  奥氮平  抑郁症  Meta分析
英文关键词:Escitalopram  Olanzapine  Depression  Meta-analysis
基金项目:
作者单位E-mail
葛祥丽 滨州医学院临床医学院滨州医学院附属医院  
李慧敬 滨州医学院临床医学院滨州医学院附属医院  
崔明湖 滨州医学院临床医学院滨州医学院附属医院 mhcui@sohu.com 
东莹莹 滨州医学院临床医学院滨州医学院附属医院  
摘要点击次数:
全文下载次数:
中文摘要:
      目的 评价艾司西酞普兰联合奥氮平治疗抑郁症的效果及安全性,以期为抑郁症治疗方案的选择提供参考。 方法 计算机检索中国知网、万方、维普、超星读秀、中国生物医学文献数据库(CBM)、PubMed、Web Of Science、Cochrane Library数据库中相关文献,按纳入与排除标准筛选文献、提取资料并评价偏倚风险后,采用Revman 5.3进行Meta分析。 结果 共纳入16篇随机对照研究,包括1 300例患者。Meta分析结果显示,艾司西酞普兰联合奥氮平组与单用艾司西酞普兰组的终点总有效率(RR=1.16,95% CI:1.05~1.28,P=0.004)和终点痊愈率(RR=1.91,95% CI:1.58~2.31,P<0.01)均有统计学意义。治疗4周(SMD=-0.95,95% CI:-1.28~-0.62,P<0.01)和治疗8周后(SMD=-1.53,95% CI:-1.84~-1.22,P<0.01),两组HAMD评分差异有统计学意义。艾司西酞普兰联合奥氮平组体质量增加(RR=6.21,95% CI:3.37~11.45,P<0.01)及嗜睡(RR=4.26,95% CI:2.17~8.36,P<0.01)发生率较单用艾司西酞普兰组高。 结论 艾司西酞普兰联合奥氮平治疗较单用艾司西酞普兰治疗对抑郁症的效果可能更好,但可能出现体质量增加及嗜睡的发生。
英文摘要:
      Objective To evaluate the efficacy and safety of escitalopram combined with olanzapine in the treatment of depression, so as to provide references for the selection of treatment programs for depression. Methods Randomized controlled trials (RCTs) about the treatment published in foreign and domestic databases, including CNKI, Wanfang Data, VIP database, Duxiu database, China Biology Medicine database (CBM), PubMed, Web Of Science and Cochrane Library were retrieved. After screening the literature according to inclusion and exclusion criteria, extracting the data and evaluating the risk of bias, Revman 5.3 was used for Meta-analysis. Results A total of 16 RCTs involving 1 300 patients were included. The results of Meta-analysis showed that the final effective rate (RR=1.16, 95% CI: 1.05~1.28, P=0.004) and final healing rate (RR=1.91, 95% CI: 1.58~2.31, P<0.01) of the escitalopram combined with olanzapine group and the escitalopram group alone were statistically significant. After treatment for 4 weeks (SMD=-0.95, 95% CI: -1.28~-0.62, P<0.01) and 8 weeks (SMD=-1.53, 95% CI: -1.84~-1.22, P<0.01), the differences in HAMD scores between the two groups were statistically significant. The incidence of weight gain (RR=6.21, 95% CI: 3.37~11.45, P<0.01) and drowsiness (RR=4.26, 95% CI: 2.17~8.36, P<0.01) of escitalopram combined with olanzapine group were higher than those of the escitalopram group alone. Conclusion Escitalopram combined with olanzapine may have a better efficacy on depression than escitalopram monotherapy, but combination therapy may result in increased weight gain and drowsiness.
      附件
查看全文  HTML  查看/发表评论  下载PDF阅读器
关闭
手机扫一扫